DelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) January 25, 2017 • 8:30 AM EST
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083 January 9, 2017 • 8:30 AM EST
DelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083 December 14, 2016 • 8:00 AM EST
DelMar Pharmaceuticals Delivers an Address and Presents an Overview of Upcoming GBM Trials with VAL-083 at the CNS Anticancer Drug Discovery Development Conference and Society for NeuroOncology Annual Meeting November 21, 2016 • 8:30 AM EST
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2017 Financial Results and Corporate Update November 14, 2016 • 8:30 AM EST
DelMar Pharmaceuticals Presents New VAL-083 Data at Two International Scientific Conferences November 7, 2016 • 8:30 AM EST
DelMar Pharmaceuticals Presents Overview of VAL-083's Unique Anticancer Mechanism at the European Association of Neuro-Oncology (EANO) Annual Meeting October 17, 2016 • 8:30 AM EDT
DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations October 13, 2016 • 8:30 AM EDT
DelMar Pharmaceuticals Presents Data Supporting the Potential of VAL-083 as a New Treatment for Ovarian Cancer at the 11th Biennial Ovarian Cancer Research Symposium September 13, 2016 • 8:30 AM EDT
DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer September 7, 2016 • 8:30 AM EDT